Hims & Hers Health & Novo Nordisk
4 shared events · Importance 3 · Last updated Feb 09, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Hims & Hers Health is facing legal threats from Novo Nordisk after their brief distribution partnership was terminated over the telehealth platform's sale of compounded Semaglutide knockoffs.
Business
Hims & Hers Health: Hims & Hers Health is facing a class action lawsuit for allegedly making false and misleading statements regarding its business practices, specifically the deceptive promotion and selling of 'knockoff' versions of Semaglutide®, which could lead to the termination of its collaboration with Novo Nordisk.
Jul 02, 2025 · 6 articles
Regulatory
Hims & Hers Health: Hims & Hers Health dropped its plan to offer a compounded version of Wegovy after the FDA threatened action, leading to a 14% drop in its stock. This decision impacts its strategy in the weight-loss medication market.
Feb 07, 2026 · 6 articles
Business
Hims & Hers Health: Hims & Hers Health launched a cheaper, off-brand version of Semaglutide, capitalizing on the demand for GLP-1 drugs, which led to legal threats from Novo Nordisk.
Feb 05, 2026 · 6 articles
Business
Hims & Hers Health: Hims & Hers Health is advertising its GLP-1 weight loss drugs, emphasizing access to healthcare, and participating in the health and telehealth advertising trend.
Feb 04, 2026 · 6 articles
NEWSDESK
Explore this relationship live
Track how Hims & Hers Health and Novo Nordisk interact across events, view sentiment trends, and discover connected entities.
Open Dashboard